The research company Pharmalundensis' principal shareholder, Staffan Skogvall, will propose delisting the company from Spotlight Stock Market ahead of the annual general meeting, according to a press release.The background is that research companies have low valuations on the Swedish market, which is considered to negatively affect negotiations with international investors."I hope that all our shareholders realize that continuing down the old path, as new share issues provide only a fraction of the capital required for our clinical studies, will only lead to further delays and eventually the company's demise. For everyone who wants to see the effect of our new drug when it is tested on diseases such as KOL, chronic fatigue syndrome and severe depression, a fresh approach and larger amounts of capital from international investors are required," says Skogvall.Skogvall holds more than 50 percent of the company's shares, split between private ownership (10.56 percent) and the company SkåneÖrnen (40.86 percent), according to the latest annual report for 2024.